Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Jenkins' Retirement From US FDA Was Several Years In The Making

Executive Summary

Outgoing Office of New Drugs director dismisses speculation that his decision to leave the agency was related to events surrounding Sarepta's controversial Exondys 51 approval.


Related Content

'Brilliant' and 'Steady' Jenkins Retiring From US FDA's Office of New Drugs
Will US FDA Wind Up With More Political Positions Under Trump?
Merck R&D Exec Jumps To US FDA As Office Of New Drugs Deputy Director
No More Sarepta-Like Development, FDA Officials Say
Finally … Rachel Sherman Takes Califf's Old FDA Job
Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate
FDA Neurology Clinical Team Leader Departure May Be Mountain Disguised As Molehill
Two Out Of Three Ain't Bad: Biosimilar User Fee Talks Completed
In Brief: OTC emergency eyewash meeting, FDA official to Perrigo, e-cigarette regulation urged, emerging markets key for J&J in OTC
FDA's Buehler To Join Teva


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts